Comparative evaluation of active and passive immunization therapy strategies targeting toxic forms of α-synuclein in Parkinson’s disease patient brain: UB-312 vaccine vs. ABBV-0805 antibodies
Yahia Kedr
31/08/2026
Progressive neurodegeneration and toxic α-synuclein aggregation are features of Parkinson's disease. Immunotherapy targeting toxic forms of α-synuclein shows promise with its two strategies, active and passive immunization therapies, but a direct comparative analysis of their mechanisms, efficacy, and translational potential remains limited, especially when it comes to long-term outcomes and patient-specific applicability.
In this study, passive immunization with ABBV-0805 and active immunization with UB-312 are contrasted through a literature review. This literature review compares and examines methods and results of preclinical and clinical trials of active immunization (UB-312) and passive immunization (ABBV-0805). In addition, evaluating them in terms of efficacy, safety, manufacturing complexity, and cost-effectiveness.
In preclinical models, UB-312 enhanced motor function without inducing inflammation and
decreased oligomeric α-synuclein in important brain regions such as the substantia nigra and
striatum. In transgenic mice, ABBV-0805 decreased phosphorylated α-synuclein, decreased soluble and insoluble aggregates, prevented the spread of pathology, and increased survival. In ex vivo human Parkinson's disease brain tissue, ABBV-0805 demonstrated selective target engagement, while early clinical studies provided preliminary pharmacokinetic and safety data. For UB-312, it produced potent, dose-dependent antibody responses with good safety. ABBV-0805 allows controlled administration of preformed antibodies, whereas UB-312 is designed to generate a sustained endogenous antibody response; whether these differences provide distinct clinical advantages remains uncertain. Both approaches demonstrated encouraging biological activity and preliminary safety profiles, supporting continued clinical investigation and the need for further validation of their therapeutic potential.